Drug firm Cadila Healthcare today said the US health regulator has issued no observations after completion of inspection of its Moraiya plant in Gujarat.
The USFDA has inspected the company’s Moraiya facility from August 31 to September 7, Cadila Healthcare said in a statement. “At the end of the inspection, no observation (483) is issued”, it added.